Clincosm LogoSign in Get a demo

Culturally Tailored Cannabis Use Disorder App

Sponsor
University of Houston (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05566730
Collaborator
National Institute on Minority Health and Health Disparities (NIMHD) (NIH), Louisiana State University Health Sciences Center in New Orleans (Other), University of Oklahoma (Other)
50
Enrollment
1
Arm
10
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The present study aims to address disparities in cannabis use outcomes among African American/Black (hereby referred to as Black) adults with cannabis use disorder (CUD). The specific aims of this study are: (1) to develop a culturally adapted, mobile app for Black cannabis users (CT-MICART) using knowledge from the current research team, published literature, expert opinion, and feedback from the Community Research Advisory Board (CRAB), (2) to pilot test CT-MICART and (3) focus on analysis of data collected as part of Aim 2.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: CT-MICART App
  • Behavioral: Control
 N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Mobile App to Address CUD Among Black Adults
Anticipated Study Start Date :
Dec 23, 2022
Anticipated Primary Completion Date :
Aug 23, 2023
Anticipated Study Completion Date :
Oct 23, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: CT-MICART App

Behavioral: CT-MICART App
App designed with the goal of treating CUD in African American adults

Behavioral: Control
App designed with the goal of treating CUD in African American adults, with participants just tracking their use of cannabis and not receiving treatment videos
Other Names:
  • Sham

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Urine Analysis [Baseline appointment and 6-week follow up appointment]

      Urine analysis for THC will be conducted at first and last appointments to determine change in cannabis use

    2. SCID-5-RV [Baseline Appointment]

      Assessment to determine whether or not potential participants have cannabis use disorder in order to determine eligibility for the study

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • at least 18 years of age

    • identify as Black/African American

    • CUD per DSM-5 (current/past month use confirmed via urine)

    • willing and able to attend a baseline visit

    • motivated to reduce cannabis (>5 on a 10-point scale)

    • score ≥ 4 on the REALM-SF indicating ≥ 6th grade English literacy level (needed to use app)

    • report cannabis use to manage anxiety/stress in the past month

    Exclusion Criteria:

    • legal mandate or substance misuse treatment

    • report of current or intended participation in a concurrent substance use treatment, including pharmacotherapy or psychotherapy for CUD not provided by researchers

    • ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety or depression

    • not being fluent in English

    • pregnant of planning to become pregnant within the next six months (assessed via self-report)

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University of Houston
    • National Institute on Minority Health and Health Disparities (NIMHD)
    • Louisiana State University Health Sciences Center in New Orleans
    • University of Oklahoma

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Lorra Garey, Principal Investigator, University of Houston
    ClinicalTrials.gov Identifier:
    NCT05566730
    Other Study ID Numbers:
    • STUDY00003690
    First Posted:
    Oct 4, 2022
    Last Update Posted:
    Dec 6, 2022
    Last Verified:
    Dec 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Marijuana Abuse

    Study Results

    No Results Posted as of Dec 6, 2022